Press release
Catalyst Biosciences Announces Poster Presentation at the 62nd Annual American Society of Hematology Conference
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials in progress poster
About this update from Gyre Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials in progress poster presentation on Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the upcoming 62nd Annual American Society of Hematology (ASH) meeting being held virtually December 5-8, 2020.\n Poster presentation details: Poster Title:The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (activated) for on-Demand Treatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, with InhibitorsPresenting Author:Linda Neuman, M.D., M.B.A., vice president, clinical development, Catalyst BiosciencesDate/Time:Sunday, December 6, 2020 / 7 am PT A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website on the day of the presentation. MarzAA, a next-generation recombinant Factor VIIa variant, is the only subcutaneously administered bypass agent in development for the treatment of Hemophilia A or B with inhibitors and other rare bleeding disorders, including Factor VII Deficiency and Glanzmann thrombasthenia. In late 2020, Catalyst Biosciences plans to dose the first patient in Crimson 1, its Phase 3 study of MarzAA for treatment of episodic bleeding in Hemophilia A and B with inhibitors. About Catalyst Biosciences Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare hematologic and complement-mediated disorders. Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Forward-Looking Statements This press...